Laurus Labs Limited (LAURUSLABS.BO)
INR 579.2
(3.34%)
INR 579.2
(3.34%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 42.71 Billion INR | 18.27% |
| 2022 | 36.11 Billion INR | 0.08% |
| 2021 | 36.08 Billion INR | 14.57% |
| 2020 | 31.49 Billion INR | 59.05% |
| 2019 | 19.8 Billion INR | 11.72% |
| 2018 | 17.72 Billion INR | 15.56% |
| 2017 | 15.34 Billion INR | 15.96% |
| 2016 | 13.22 Billion INR | -3.2% |
| 2015 | 13.66 Billion INR | 21.83% |
| 2014 | 11.21 Billion INR | 22.63% |
| 2013 | 9.14 Billion INR | 105.95% |
| 2012 | 4.44 Billion INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2024 Q2 | 45.85 Billion INR | 0.0% |
| 2023 Q4 | 42.71 Billion INR | 0.0% |
| 2023 Q2 | 40.14 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 FY | 42.71 Billion INR | 18.27% |
| 2022 Q2 | 42.82 Billion INR | 0.0% |
| 2022 Q4 | 36.11 Billion INR | 0.0% |
| 2022 FY | 36.11 Billion INR | 0.08% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2021 Q2 | 33.57 Billion INR | 0.0% |
| 2021 FY | 36.08 Billion INR | 14.57% |
| 2021 Q4 | 36.08 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q1 | - INR | -100.0% |
| 2020 Q4 | 31.49 Billion INR | 0.0% |
| 2020 FY | 31.49 Billion INR | 59.05% |
| 2020 Q2 | 20.63 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q1 | - INR | -100.0% |
| 2019 Q4 | 19.8 Billion INR | 0.0% |
| 2019 FY | 19.8 Billion INR | 11.72% |
| 2019 Q2 | 20 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q3 | - INR | -100.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q4 | 17.72 Billion INR | 0.0% |
| 2018 FY | 17.72 Billion INR | 15.56% |
| 2018 Q1 | - INR | -100.0% |
| 2018 Q2 | 17.8 Billion INR | 0.0% |
| 2017 Q2 | 15.55 Billion INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q4 | 15.34 Billion INR | 0.0% |
| 2017 FY | 15.34 Billion INR | 15.96% |
| 2016 Q2 | 15.65 Billion INR | 0.0% |
| 2016 FY | 13.22 Billion INR | -3.2% |
| 2016 Q4 | 13.22 Billion INR | 0.0% |
| 2016 Q1 | - INR | 0.0% |
| 2015 FY | 13.66 Billion INR | 21.83% |
| 2014 FY | 11.21 Billion INR | 22.63% |
| 2013 FY | 9.14 Billion INR | 105.95% |
| 2012 FY | 4.44 Billion INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 16.27 Billion INR | -162.475% |
| Aurobindo Pharma Limited | 152.2 Billion INR | 71.937% |
| Glenmark Life Sciences Limited | 5.18 Billion INR | -724.463% |
| Granules India Limited | 22.95 Billion INR | -86.085% |
| Indoco Remedies Limited | 10.34 Billion INR | -313.009% |
| Achyut Healthcare Limited | 2.01 Million INR | -2121837.407% |
| Ajanta Pharma Limited | 10.71 Billion INR | -298.818% |
| Alkem Laboratories Limited | 48.6 Billion INR | 12.119% |
| Alpa Laboratories Limited | 307.12 Million INR | -13808.024% |
| Brooks Laboratories Limited | 248.6 Million INR | -17081.99% |
| AstraZeneca Pharma India Limited | 3.66 Billion INR | -1066.712% |
| Bajaj HealthCare Limited | 4.86 Billion INR | -777.517% |
| Bliss GVS Pharma Limited | 2.1 Billion INR | -1925.492% |
| Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 60.068% |
| Eris Lifesciences Limited | 38.26 Billion INR | -11.619% |
| FDC Limited | 3.7 Billion INR | -1051.583% |
| Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 34.397% |
| Gufic Biosciences Limited | 5.59 Billion INR | -662.787% |
| Ind-Swift Laboratories Limited | 2.28 Billion INR | -1765.706% |
| Ipca Laboratories Limited | 33.74 Billion INR | -26.589% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -14293.651% |
| Krebs Biochemicals & Industries Limited | 2.97 Billion INR | -1336.309% |
| Lasa Supergenerics Limited | 541.92 Million INR | -7782.013% |
| Lupin Limited | 96.23 Billion INR | 55.615% |
| Mankind Pharma Limited | 23.87 Billion INR | -78.912% |
| Medicamen Biotech Limited | 940.36 Million INR | -4442.333% |
| Medico Remedies Limited | 438.24 Million INR | -9646.762% |
| Megasoft Limited | 1.85 Billion INR | -2204.981% |
| NATCO Pharma Limited | 10.53 Billion INR | -305.57% |
| Piramal Pharma Limited | 74 Billion INR | 42.281% |
| RPG Life Sciences Limited | 1.38 Billion INR | -2994.812% |
| Sigachi Industries Limited | 2.53 Billion INR | -1587.48% |
| Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 76.731% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | -1999.793% |
| Syncom Formulations (India) Limited | 1.16 Billion INR | -3565.825% |
| Unichem Laboratories Limited | 8.06 Billion INR | -429.35% |
| Wanbury Limited | 3.15 Billion INR | -1253.648% |
| Windlas Biotech Limited | 1.76 Billion INR | -2323.248% |
| ZIM Laboratories Limited | 2.08 Billion INR | -1952.834% |
| Zydus Lifesciences Limited | 71.79 Billion INR | 40.502% |
| Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | -997.244% |
| Divi's Laboratories Limited | 18.99 Billion INR | -124.932% |
| Hester Biosciences Limited | 3.59 Billion INR | -1088.259% |
| Procter & Gamble Health Limited | 2.56 Billion INR | -1567.757% |
| Amrutanjan Health Care Limited | 783.82 Million INR | -5349.514% |
| Bal Pharma Limited | 2.51 Billion INR | -1600.912% |
| Strides Pharma Science Limited | 37.68 Billion INR | -13.36% |
| Venus Remedies Limited | 1.39 Billion INR | -2966.815% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | -417.709% |
| Nectar Lifesciences Limited | 11.21 Billion INR | -280.766% |
| Shilpa Medicare Limited | 12.93 Billion INR | -230.289% |
| Aarti Drugs Limited | 11.5 Billion INR | -271.302% |
| IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | -574.913% |
| Suven Life Sciences Limited | 148.62 Million INR | -28640.622% |
| Ind-Swift Limited | 13.45 Billion INR | -217.511% |
| Valiant Laboratories Limited | 1.05 Billion INR | -3936.309% |
| J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | -298.904% |
| Solara Active Pharma Sciences Limited | 14.14 Billion INR | -202.002% |
| Themis Medicare Limited | 1.88 Billion INR | -2163.012% |
| Hikal Limited | 12.99 Billion INR | -228.703% |
| Torrent Pharmaceuticals Limited | 82.05 Billion INR | 47.941% |
| Sequent Scientific Limited | 8.27 Billion INR | -416.235% |
| Novartis India Limited | 1.8 Billion INR | -2271.584% |
| Wockhardt Limited | 39.87 Billion INR | -7.135% |
| Jubilant Pharmova Limited | 61.27 Billion INR | 30.289% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -14690.425% |
| Neuland Laboratories Limited | 5.49 Billion INR | -676.832% |
| Morepen Laboratories Limited | 4.45 Billion INR | -857.772% |
| Kilitch Drugs (India) Limited | 643.88 Million INR | -6533.907% |
| Mangalam Drugs & Organics Limited | 1.97 Billion INR | -2061.33% |